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Background. Irritable bowel syndrome (IBS) is associated with depression and depression with impaired cognitive functions. The
primary aim was to study associations between depression and cognitive functions in patients with IBS.Methods. IBS (according to
the Rome III criteria), cognitive functions (evaluated with a set of neuropsychological tests), and depression (measured with Beck
Depression Inventory II and Montgomery-A˚sberg Depression Scale) were analysed in patients with idiopathic depression and in
patients with unspecified neurological symptoms. Results. 18 and 48 patients with a mean age of 47 and 45 years were included in
the “Depression” and “Neurological” group, respectively. In the “Depression” group, the degree of depression was significantly
higher in patients with IBS than in those without. Depression was associated with impaired cognitive function in 6 out of 17
neuropsychological tests indicating reduced set shifting, verbal fluency, attention, and psychomotor speed. IBS was statistically
significantly associated with depression but not with any of the tests for cognitive functions. Conclusions. IBS was associated with
depression but not with impaired cognitive functions. Since the idiopathic depression was associated with cognitive deficits, the
findings could indicate that the depression in patients with IBS differs from an idiopathic depression.
1. Introduction
Irritable bowel syndrome (IBS) is a common disorder with
a high prevalence of comorbidities such as musculoskeletal
pain, anxiety and depression, and emotional disturbances
and is common in patients with an idiopathic depression [1–
4]. The two disorders, IBS and the idiopathic depression, are
associated and have in common several pathophysiological
abnormalities [5, 6]. The interaction between the gut and the
brain called the “brain-gut axis” is mediated via humoral,
immunological, and neuronal pathways.The axis is of impor-
tance for health and disease including gastrointestinal and
psychological functions [7].
Cognitive deficits are common in patients with an idi-
opathic depression but have been less well studied in patients
with IBS. The associations between IBS and cognitive func-
tions are contradictory in part due to different methods
for evaluation of the cognition [8–13]. The main reason for
this study was the contradictory information about cognitive
functions in patients with IBS, particularly the association
between depression and cognitive functions. Knowledge
about the association between depression and cognitive
functions in patients with IBS is important for a better
understanding of the “brain-gut axis” and a correct evaluation
of the patients. Kennedy et al. pinpoint the lack of knowledge
very well: “. . .it will be necessary to carefully control for
psychiatric co-morbidity so that the relative contributions of
anxiety and depression to deficits in cognitive functioning can
be disentangled from the alterations associated with IBS alone”
[14].
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This study was designed to compare patients with an idio-
pathic depression and unspecified neurological symptoms.
The protocol specified the supplementary analyses related
to IBS. The primary aim of these analyses was to study the
associations between depression and cognitive functions in
patients with IBS.
2. Methods
2.1. Design and Participants
2.1.1. Design. Design was cross-sectional studies in two
groups of patients.
(i) Consecutive patients above 17 years of age with
the diagnosis of idiopathic depression (according
to ICD-10; F 32–34 spectre, without triggering fac-
tors) referred to a psychiatric outpatient clinic were
included in the study after exclusion of organic
diseases (the “Depression” group).
(ii) Consecutive patients above 17 years of age admitted to
an inpatient neurological clinic for thorough investi-
gations of neurological symptoms were included after
exclusion of organic disorders (the “Neurological”
group). The patients had no objective neurological
signs, all laboratory tests were normal, and all supple-
mentary investigations (CT, MRI, spinal fluid exam-
ination, etc.) which were performed at the clinicians’
discretion were normal. The patients presented with
various symptoms such as headache, back pain, and
vertigo.
A medical history was recorded, a routine clinical exam-
ination was performed, and haematological and biochemical
screening tests were taken in all patients. In order to exclude
other diseases, other tests were accomplished according to
the doctors’ discretion. All patients filled in validated ques-
tionnaires for the classification of gastrointestinal disorders
and depression. A set of neuropsychological tests was carried
out. An experienced psychiatric study nurse performed the
practical work with the questionnaires and the neuropsycho-
logical testing.
2.2. Variables. The following variables were used.
2.2.1. Demographics. The demographics were the following.
(i) Gender; age (years); education (number of years in
school).
2.2.2. Abdominal Complaints. The abdominal complaints
were assessed as follows.
(i) IBS (yes/no) was assessed with a validated Norwegian
version of the internationally accepted Rome III
questionnaire [15, 16].
(ii) The degree of abdominal symptoms was measured
with Irritable Bowel Severity Scoring System (IBSSS)
(mild 75–174; moderate 175–300; and severe 301–500)
[15, 16].
2.2.3. Depression. Two valid and reliable questionnaires were
used for the scoring of depression.
(i) Beck Depression Inventory v. II (BDI-II): minimal
depression 0–13; mild depression 14–19; moderate
depression 20–28; and severe depression 29–63 [17].
(ii) Montgomery-A˚sberg Depression Scale (MADRS):
normal/symptom absent 0–6; mild depression 7–19;
moderate depression 20–34; and severe depression
35–60 [18].
2.2.4. Cognitive Function. Several valid and reliable tests were
used for the evaluation of cognitive functions [19]. The tests
evaluate different aspects of the cognitive functions.
(i) Mini-Mental State Examination (MMSE) (score 0–30,
normal ≥ 24) is a test for dementia [20].
(ii) Trail Making Test A (simple) (ref. value 30 (SD 10)
seconds); Trail Making Test B (complex) (ref. value
60 (SD 15) seconds): the Trail Making Test measures
attention, visual searching, mental processing speed,
set shifting, and cognitive flexibility. Low scores are
best.
(iii) Grooved Pegboard Test is a test of fine motor control.
The test measures time in seconds with dominant
hand (ref. value 63 (SD 10) seconds) and nondomi-
nant hand (ref. value 69 (SD 15) seconds). Low scores
are best.
(iv) Hopkins Verbal Learning Test (HVLT) immediate
total recall (score 0–36) and HVLT delayed recall
(score 0–12) are tests of verbal immediate and delayed
recall. High scores are best.
(v) Brief Visual Memory Test (BVMT) immediate total
recall (score 0–36) and BVMT delayed recall (score
0–12) measure immediate and delayed visual recall.
Both tests measure the number of words or items the
participant can recall. High scores are best.
(vi) Wechsler Adult Intelligence Scale 3rd Edition (WAIS-
III) Vocabulary (ref. value raw score 46) measures
the patients’ ability to define and explain different
words. WAIS-III Digit Symbol (ref. value raw score
64) andWAIS-III Symbol Search (ref. value raw score
26) measure processing speed, visual perception,
attention and concentration, and motor and mental
speed (number of correct answers within a period)
[21, 22].
(vii) Stroop Test 1 (Word) (colour naming) (ref. value 41,
SD 7); Stroop Test 2 (Colour) (colour name reading)
(ref. value 53, SD 9); Stroop Test 3 (Interference)
(colour interference) (ref. value 85, SD 18) [23]: the
Stroop tests measure attention, cognitive processing,
and mental stimulus control. The results are given as
time in seconds. Low scores are best.
(viii) Controlled Oral Word Association Test (COWAT)
(Words) (number of Words on F, A, and S) (ref.
value 31, SD 5); COWAT (Cloths) (number of
cloths) (ref. value 13, SD 3); COWAT (Animals)
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Table 1: Patient characteristics and comparisons between the “Neurological” and “Depression” groups.
Patient characteristics “Neurological” “Depression” Statistics
Gender (female/male) 12 (63%)/7 (37%) 25 (53%)/22 (47%) 𝑝 = 0.59
Age (years) 47.3 (14.5) 44.7 (14.0) 𝑝 = 0.51
Education (years) 13 (10–17) 13 (10–17) 𝑝 = 0.15∗
IBS 6 (32%) 27 (57%) 𝑝 = 0.07
IBSSS 113 (88) 200 (103) p = 0.003
BDI-II 5 (0–26) 29 (10–54) p < 0.001∗
MADRS 8.1 (5.9) 27.5 (8.1) p < 0.001
MMSE 29 (27–30) 29 (23–30) 𝑝 = 0.12∗
Trail Making A (simple) 34 (20–145) 45 (22–153) p = 0.01∗
Trail Making B (complex) 71 (45–181) 88 (49–361) p = 0.02∗
Grooved Pegboard Test (dominant hand) 70 (54–112) 78 (53–176) 𝑝 = 0.14∗
Grooved Pegboard Test (not dominant hand) 74 (55–135) 87 (61–228) p = 0.02∗
HVLT immediate total recall 26 (10–29) 23 (11–34) 𝑝 = 0.29∗
HVLT delayed recall 10 (1–12) 9 (10–12) 𝑝 = 0.37∗
BVMT immediate total recall 20.7 (5.4) 19.7 (6.9) 𝑝 = 0.51
BVMT delayed recall 8.6 (2.3) 7.7 (2.5) 𝑝 = 0.19
WAIS-III Vocabulary 43.0 (6.7) 44.0 (8.5) 𝑝 = 0.65
WAIS-III Digit Symbol 60.3 (15.1) 51.8 (16.9) 𝑝 = 0.06
WAIS-III Symbol Search 28.1 (8.7) 25.0 (8.2) 𝑝 = 0.19
Stroop 1 (Word) 32 (25–45) 38 (25–67) p = 0.003∗
Stroop 2 (Colour) 26 (20–39) 29.0 (19–52) 𝑝 = 0.17∗
Stroop 3 (Interference) 54 (39–118) 61 (43–141) 𝑝 = 0.36∗
COWAT (Words on F, A, and S) 27 (18–75) 33 (13–69) 𝑝 = 0.31∗
COWAT (Cloths) 19.4 (4.9) 17.6 (5.1) 𝑝 = 0.21
COWAT (Animals) 22.8 (6.2) 18.6 (5.4) p = 0.008
The results are given as the number (proportion in per cent), mean (SD), and median (range) and analysed with exact unconditional table analyses, 𝑡-test, and
Mann-Whitney 𝑈 test (marked with ∗).
(number of animals) (ref. value 17, SD 5) [24–26]:
these are all verbal fluency tests that includemeasures
of verbal, cloths, and animal material. The tests
measure the ability to generate words beginning with
a given letter or category within one minute. High
scores are best.
2.3. Statistics. The characteristics of the patients were anal-
ysed with descriptive statistics and reported as mean (SD),
median (range), and proportion (percentage). Comparisons
between the groups were analysed with an exact uncondi-
tional test for 2 × 2 tables, 𝑡-test, and Mann-Whitney 𝑈
test depending on the type of the data and the normality.
Predictors of depression and cognitive functionswere studied
with univariate general linear model analyses with the scores
for depression and cognitive functions (one at a time) as
dependent variables. Independent variables were the groups
“Neurological”/“Depression,” “no IBS”/“IBS,” gender (fixed
factors), and age and education (covariates). For the calcu-
lation of estimated marginal means, the interaction between
the groups “Neurological”/“Depression” and “IBS”/“no IBS”
was added to the model. Except for the adjustments made
in the multivariable analyses, no adjustments were made for
multiple comparisons.
3. Results
3.1. Patients. Out of 71 patients included in the study for com-
parisons between patients in the “Neurological” and “Depres-
sion” group, 5 in the “Neurological” group were excluded
because of organic abdominal diseases or incompletely filled-
in questionnaires. This left 66 patients for the analyses: 18 in
the “Neurological” group and 48 in the “Depression” group.
3.2. Descriptive and Univariable Analyses. Table 1 gives the
characteristics of the participants with comparisons between
the groups. Compared to the patients in the “Neurological”
group, the patients in the “Depression” group had statistically
significantly higher scores for depression and abdominal
complaints (IBSSS), significantly impaired cognitive func-
tions on 5 out of 17 tests, and a trend for a higher prevalence of
IBS. Attention, cognitive processing, and verbal fluency were
the cognitive functions with the most marked differences
between the groups. Tables 2 and 3 compare patients with and
without IBS in the two groups. The cognitive functions did
not differ significantly between the patients with and without
IBS in any of the two groups. In the “Depression” group,
depression and abdominal complaints were significantly
more severe in patients with IBS.
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Table 2: Patient characteristics and comparisons of patients with and without IBS in the “Neurological” group.
Patient characteristics No IBS IBS Statistics
Gender (female/male) 8 (62%)/5 (38%) 4 (67%)/2 (33%) 𝑝 = 0.85
Age (years) 46.5 (15.6) 49.2 (12.7) 𝑝 = 0.72
Education (years) 13 (10–17) 13.5 (10–17) 𝑝 = 0.90∗
IBSSS 87.9 (67.8) 164.5 (107.9) 𝑝 = 0.08
BDI-II 5 (0–26) 4.5 (2–19) 𝑝 = 0.90∗
MADRS 6.9 (5.0) 10.5 (7.5) 𝑝 = 0.23
MMSE 30 (28–30) 28.5 (27–30) 𝑝 = 0.24∗
Trail Making A (simple) 32 (20–67) 36 (24–145) 𝑝 = 0.52∗
Trail Making B (complex) 71 (45–130) 69.5 (61–181) 𝑝 = 0.83∗
Grooved Pegboard Test (dominant hand) 70 (54–94) 68 (56–112) 𝑝 = 0.90∗
Grooved Pegboard Test (not dominant hand) 73 (55–131) 75 (62–135) 𝑝 = 0.64∗
HVLT immediate total recall 23 (10–29) 26.5 (20–29) 𝑝 = 0.28∗
HVLT delayed recall 10 (1–12) 10 (6–11) 𝑝 = 0.58∗
BVMT immediate total recall 21.0 (6.0) 20.2 (4.1) 𝑝 = 0.76
BVMT delayed recall 8.4 (2.6) 9.1 (1.6) 𝑝 = 0.51
WAIS-III Vocabulary 41.7 (6.6) 45.8 (6.3) 𝑝 = 0.22
WAIS-III Digit Symbol 62.8 (16.3) 54.7 (11.7) 𝑝 = 0.29
WAIS-III Symbol Search 29.8 (8.1) 24.3 (9.5) 𝑝 = 0.21
Stroop 1 (Word) 31 (25–44) 33 (30–45) 𝑝 = 0.15∗
Stroop 2 (Colour) 24 (20–39) 26.5 (22–28) 𝑝 = 0.42∗
Stroop 3 (Interference) 54 (39–118) 58 (48–104) 𝑝 = 0.77∗
COWAT (words on F, A, and S) 31 (18–75) 25 (22–34) 𝑝 = 0.24∗
COWAT (Cloths) 19.7 (5.5) 18.5 (3.6) 𝑝 = 0.62
COWAT (Animals) 23.2 (7.4) 22.2 (2.0) 𝑝 = 0.76
The results are given as the number (proportion in per cent), mean (SD), and median (range) and analysed with exact unconditional table analyses, 𝑡-test, and
Mann-Whitney 𝑈 test (marked with ∗).
3.3. Univariate Regression Analyses. IBS was an indepen-
dent predictor of depression but was not associated with
differences in any of the tests for cognitive functions. The
“Depression” group was associated with significantly reduced
cognitive performance in 6 of the 17 tests. The most marked
differences were seen in the tests for attention and cognitive
processing (Stroop 1 (Word)) and verbal fluency (COWAT
(Animal)). Table 4 gives the details. Figure 1 visualises the
associations between the groupswith andwithout IBS and the
“Neurological” and “Depression” groups for some selected
variables (BDI-II, Trail Making Test B, and HVLT immediate
total recall). Both the “IBS” group and the “Depression”
group were significantly associated with BDI-II, only the
“Depression” group was associated with Trail Making Test B,
and none of themwas associated with HVLT immediate total
recall.
4. Discussion
The main finding was that the cognitive functions measured
with a broad spectre of reliable and validated tests were
unrelated to IBS. In accordance with other studies, this
study showed associations between IBS and depression and
between the idiopathic depression and cognitive functions.
We are not aware of previous studies on the association
between IBS and cognitive functions after adjusting for
the idiopathic depression. These new findings are of impor-
tance for the clinical evaluation of patients with IBS. Since
depression and other comorbidities are common in patients
with IBS, physicians might wrongly suspect those with
depression or cognitive impairment.
The normal cognitive functioning in patients with IBS
has, with some exceptions, also been reported in other
studies [9, 10, 14]. Kennedy et al. used several tests including
Paired Associates Learning (PAL) test.They reported a subtle
visuospatial memory deficit that remained after correction
for psychiatric comorbidity, in one out of 5 PAL subtests,
but no change in any of the other tests [10]. Brain imag-
ing (functional magnetic resonance imaging and positron
emission tomography) and neurophysiological recordings
(cerebral evoked potentials, magnetoencephalography, and
spinal reflex responses) have shown abnormal findings in
patients with IBS. The clinical relevance of these findings,
such as the relation to affective and cognitive functions, has
not been established [27, 28].
The results have theoretical and practical implications.
Theoretically, impaired cognitive performance was expected
since patients with IBS are often depressed and patients
with depression have impaired cognitive performance. The
aetiology, pathogenesis, and pathophysiology of depression
are complex and might differ between various forms of
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Table 3: Patient characteristics and comparisons of patients with and without IBS in the “Depression” group.
Patient characteristics “No IBS” “IBS” Statistics
Gender (female/male) 12 (60%)/8 (40%) 13 (48%)/14 (52%) 𝑝 = 0.47
Age (years) 46.3 (16.1) 43.6 (12.4) 𝑝 = 0.52
Education (years) 12 (7–17) 13 (9–17) 𝑝 = 0.42∗
IBSSS 159 (109) 230 (89) p = 0.02
BDI-II 22.5 (10–49) 37 (10–54) p = 0.007∗
MADRS 24.7 (7.3) 29.5 (8.2) p = 0.04
MMSE 29 (23–30) 29 (25–30) 𝑝 = 0.34∗
Trail Making A (simple) 44.5 (22–113) 45 (24–153) 𝑝 = 0.95∗
Trail Making B (complex) 88.5 (49–361) 88 (50–361) 𝑝 = 0.85∗
Grooved Pegboard Test (dominant hand) 83.5 (53–176) 76 (54–163) 𝑝 = 0.36∗
Grooved Pegboard Test (not dominant hand) 89.0 (61–172) 87 (63–228) 𝑝 = 0.48∗
HVLT immediate total recall 23.5 (11–29) 23.0 (15–34) 𝑝 = 0.81∗
HVLT delayed recall 9 (1–12) 9 (5–12) 𝑝 = 0.74∗
BVMT immediate total recall 19.5 (6.5) 19.9 (7.3) 𝑝 = 0.85
BVMT delayed recall 8.0 (2.3) 7.6 (2.7) 𝑝 = 0.64
WAIS-III Vocabulary 42.5 (8.7) 45.1 (8.3) 𝑝 = 0.31
WAIS-III Digit Symbol 52.6 (21.1) 51.1 (13.2) 𝑝 = 0.80
WAIS-III Symbol Search 24.0 (8.6) 25.9 (8.0) 𝑝 = 0.44
Stroop 1 (Word) 38 (29–56) 38 (25–67) 𝑝 = 1.00∗
Stroop 2 (Colour) 28.5 (19–45) 29 (19–52) 𝑝 = 0.96∗
Stroop 3 (Interference) 67 (43–141) 57 (44–127) 𝑝 = 0.43∗
COWAT (Words on F, A, and S) 33 (13–54) 32 (18–69) 𝑝 = 0.68∗
COWAT (Cloths) 17.9 (5.7) 17.4 (4.6) 𝑝 = 0.75
COWAT (Animals) 18.2 (5.2) 19.0 (5.7) 𝑝 = 0.64
The results are given as the number (proportion in per cent), mean (SD), and median (range) and analysed with exact unconditional table analyses, 𝑡-test, and
Mann-Whitney 𝑈 test (marked with ∗).
depression such as “idiopathic depression,” “reactive depres-
sion,” and “inflammation associated depression” [29–31].
Depression might be several diseases or disorders with
unequal associations with cognitive functioning and different
associations with the brain-gut axis.
The findings are also of importance for clinical practice.
Patients with IBS are sometimes regarded as “nagging”
persons since they present with a wide range of comorbidities
including anxiety, depression, muscle-skeletal pain, unex-
plained somatic symptoms, and poor social functioning.This
study showed that their cognitive and intellectual functions
were unaffected and indirectly indicates that their comorbid-
ity is “real.” The findings should remind the clinicians not to
assign patientswith IBS ofmore comorbidities thannecessary
and to handle the symptoms they present seriously.
The tight association between IBS and depression shown
in this study is well known from other studies, as is the
association between depression and cognitive performance
[1–3, 8, 32–34]. This study showed that the cognitive func-
tions in patients with depression were unequally affected. A
significant impairment was related to the visual scanning,
motor speed, and set shifting (the Trail Making Tests and the
Stroop Tests) and to fine motor control and tempo (Grooved
Pegboard Tests). The capacity for immediate and delayed
recall (the HVLT and BVMT) was unaffected. The impaired
WAIS-III Digit Symbol test, which has been evaluated as
one of the most sensitive WAIS-III tests, could indicate
intellectual impairment. Other functional differences were
less clear. Overall, the results indicate that the set shifting, ver-
bal fluency, attention, and psychomotor speed were reduced
in patients with depression, whereas other functions were
normal.
The gut and the brain interact through a bidirec-
tional neuronal, humoral, and immunological communi-
cation referred to as the brain-gut axis that affects both
gastrointestinal and psychological functioning [7]. The sys-
tem is only partly understood, but the influence of the gut
microbiota and the function of the blood-brain barrier on
the system have been ascertained [35, 36]. Both IBS and
depression are influenced by the brain-gut axis and have
some common pathophysiological abnormalities that could
explain the associations between the two disorders [5, 6,
31, 37]. The importance of the brain-gut axis for cognitive
functioning is unknown. The finding that there were no
associations between the gut and cognitive functions could
indicate that the interaction between the gut and depression
differs from the interaction between the gut and cognitive
functions.
4.1. Strengths and Limitations. The use of a wide range of
valid and reliable neuropsychological tools for the evaluation
of cognitive functions is a significant strength of this study.
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Table 4: The associations between depression and cognitive functions and the groups “Neurological”/“Depression” and “no IBS”/“IBS.” The
results of linear regression analyses after adjusting for age, sex, and years of education.
Dependent variables
Independent variables
“Neurological”/“Depression”
𝐵 (95% CI); 𝑝 value
“No IBS”/“IBS”
𝐵 (95% CI); 𝑝 value
BDI-II 22.0 (16.0 : 28.0); p < 0.001 7.3 (1.9 : 12.7); p = 0.009
MADRS 18.1 (14.1 : 22.1); p < 0.001 3.8 (0.2 : 7.4); p = 0.038
MMSE
−0.6 (−1.5 : 0.3); 𝑝 = 0.19 0.0 (−0.8 : 0.8); 𝑝 = 0.94
Trail Making Test A (simple) 11.0 (−3.6 : 25.7); 𝑝 = 0.14 7.0 (−6.1 : 20.1); 𝑝 = 0.29
Trail Making Test B (complex) 40.7 (4.2 : 77.2); p = 0.029 −2.6 (−35.3 : 30.1); 𝑝 = 0.87
Grooved Pegboard Test (dominant hand) 15.7 (3.3 : 28.0); p = 0.014 −6.9 (−18.0 : 4.1); 𝑝 = 0.22
Grooved Pegboard Test (not dominant hand) 19.9 (3.6 : 36.1); p = 0.017 −5.1 (−19.7 : 9.4); 𝑝 = 0.48
HVLT immediate total recall
−1.3 (−3.9 : 1.3); 𝑝 = 0.33 1.3 (−1.0 : 3.7); 𝑝 = 0.26
HVLT delayed recall
−0.5 (−1.9 : 0.8); 𝑝 = 0.41 0.2 (−0.9 : 1.4); 𝑝 = 0.69
BVMT immediate total recall
−0.9 (−4.3 : 2.6); 𝑝 = 0.63 −0.2 (−3.3 : 2.9); 𝑝 = 0.89
BVMT delayed recall
−1.1 (−2.4 : 0.2); 𝑝 = 0.11 −0.1 (−1.3 : 1.1); 𝑝 = 0.86
WAIS-III Vocabulary 2.3 (−1.4 : 6.1); 𝑝 = 0.22 2.4 (−1.0 : 5.8); 𝑝 = 0.16
WAIS-III Digit Symbol
−8.5 (−15.9 :−1.2); p = 0.024 −3.4 (−10.0 : 3.3); 𝑝 = 0.31
WAIS-III Symbol Search
−3.5 (−7.1 : 0.1); 𝑝 = 0.056 −0.5 (−3.8 : 2.7); 𝑝 = 0.74
Stroop 1 (Word) 5.6 (1.6 : 9.7); p = 0.007 1.0 (−2.6 : 4.6); 𝑝 = 0.57
Stroop 2 (Colour) 2.2 (−1.2 : 5.7); 𝑝 = 0.19 0.4 (−2.7 : 3.4); 𝑝 = 0.82
Stroop 3 (Interference) 9.5 (−1.5 : 20.6); 𝑝 = 0.09 −3.9 (−13.8 : 6.0); 𝑝 = 0.44
COWAT (Words on F, A, and S) 3.4 (−4.2 : 10.9); 𝑝 = 0.37 −0.1 (−6.9 : 6.6); 𝑝 = 0.97
COWAT (Cloths)
−1.2 (−3.8 : 1.3); 𝑝 = 0.34 −0.6 (−2.9 : 1.6); 𝑝 = 0.58
COWAT (Animals)
−4.5 (−7.6 :−1.4); p = 0.005 0.3 (−2.4 : 3.1); 𝑝 = 0.82
Some other studies have used tool measuring psycho-social-
emotional-thinking and not strict neuropsychological func-
tioning that could explain the contradictory results [12, 13].
The case-control design of the study was planned for
comparisons between patients with and without depression
and was not ideal for the study of IBS. Nevertheless, the
design made the planned comparisons between patients with
and without IBS in the two groups possible, and the analyses
were according to the protocol.The “Neurological” groupwas
used as controls because no somatic or psychiatric disorder
could explain their unspecific neurological symptoms. A
completely healthy control groupwould have been preferable.
In addition to their unspecific neurological symptoms, the
“Neurological” group had a high prevalence of comorbidities
such as IBS and abdominal complaints and perhaps affective
and cognitive disorders.
IBSSS has been validated for the scoring of symptoms in
subjects with IBS and not for the scoring of all functional
gastrointestinal disorders, as it was used in this study. This
use of IBSSS makes the results of the IBSSS less reliable and
explains the high scores in patients without IBS.
The lack of any significant differences between patients
with and without IBS in the “Neurological” group was
probably a type II error due to the small sample size. Not even
the IBSSS differed between the groups, which indicated a high
prevalence of gastrointestinal symptoms also in subjects
without IBS.
There was no tendency toward cognitive deficits in
patients with IBS despite having significantly more depres-
sion. The total sample size was limited, and a type II error
cannot be excluded. If an association between IBS and
cognitive deficits has been missed, the association must be
weaker than between IBS and depression, which was highly
significant.
5. Conclusions
There were no significant associations between IBS and
cognitive functions. IBS was associated with depression,
and the idiopathic depression was associated with cogni-
tive deficits. The findings could indicate that depression in
patients with IBS differs from an idiopathic depression and
that the interaction between the gut and depression differs
from that of the gut and cognitive functions.
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